MedPath

Probiotic in adult sepsis patients

Phase 3
Conditions
Health Condition 1: B968- Other specified bacterial agents as the cause of diseases classified elsewhere
Registration Number
CTRI/2021/06/034058
Lead Sponsor
Postgraduate Institute of Medical Education and Research Chandigarh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Age:18-90 years

2.An increase in SOFA score of 2 or more alongwith documented source of infection anywhere, proven either clinically or by laboratory/radiological investigation/s

Exclusion Criteria

1)Age less than 18 years

2)Contraindication to start enteral feed,

3)Immunodeficiency or malignancy,

4)Prior steroids or immunotherapy,

5)Probiotics intake in last one month

6)Those who are not giving written consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine any reduction in hospital mortality and 28 day mortality in patients with confirmed diagnosis of sepsis receiving enteral high dose probiotic supplementationTimepoint: At hospital disposition and 28 days after randomization
Secondary Outcome Measures
NameTimeMethod
Ascertain the effect of enteral probiotic supplementation on: <br/ ><br>1. Duration of ICU/hospital stay <br/ ><br>2. Duration of mechanical ventilation, in patients requiring mechanical ventilation <br/ ><br>3.Requirement of renal replacement therapy <br/ ><br>4.Requirement of vasoactive agents and duration of such need <br/ ><br>5. Trends of severity of illness [APACHE II] and organ dysfunction scores (SOFA) <br/ ><br>Timepoint: At patients disposal from hospital and at 28 days from inclusion in study
© Copyright 2025. All Rights Reserved by MedPath